Drugs / Autologous CD19-Targeted CAR-T Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07432334 | Mar 2026 → Sep 2027 expected | systemic lupus erythematosus | Vinmec Research Institute of Stem Cell and Gene Technology | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD19-Targeted CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07432334 ↗ |
| Action | Deplete | “including B-cell depletion and reconstitution” NCT07432334 ↗ |
| Modality | Cell therapy | “autologous CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy” NCT07432334 ↗ |
| Route | Intravenous | “single intravenous infusion of approximately 1.0 × 10⁶ CD19 CAR-T cells per kilogram of body weight” NCT07432334 ↗ |
| Target | CD19 | “Autologous chimeric antigen receptor T cells targeting CD19” NCT07432334 ↗ |